240 related articles for article (PubMed ID: 19389560)
1. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
Armstrong PW; Fu Y; Westerhout CM; Hudson MP; Mahaffey KW; White HD; Todaro TG; Adams PX; Aylward PE; Granger CB
J Am Coll Cardiol; 2009 Apr; 53(17):1503-9. PubMed ID: 19389560
[TBL] [Abstract][Full Text] [Related]
2. Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
Kaul P; Fu Y; Westerhout CM; Granger CB; Armstrong PW
Am J Cardiol; 2012 Dec; 110(11):1555-60. PubMed ID: 22920928
[TBL] [Abstract][Full Text] [Related]
3. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Siha H; Das D; Fu Y; Zheng Y; Westerhout CM; Storey RF; James S; Wallentin L; Armstrong PW
CMAJ; 2012 Jul; 184(10):1135-42. PubMed ID: 22546885
[TBL] [Abstract][Full Text] [Related]
4. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
Bagai A; Armstrong PW; Stebbins A; Mahaffey KW; Hochman JS; Weaver WD; Patel MR; Granger CB; Lopes RD
Am Heart J; 2013 Nov; 166(5):913-9. PubMed ID: 24176448
[TBL] [Abstract][Full Text] [Related]
6. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
[TBL] [Abstract][Full Text] [Related]
7. Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex.
Kholaif N; Zheng Y; Jagasia P; Himmelmann A; James SK; Steg PG; Storey RF; Westerhout CM; Armstrong PW
Am J Med; 2015 Aug; 128(8):914.e11-9. PubMed ID: 25818495
[TBL] [Abstract][Full Text] [Related]
8. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
[TBL] [Abstract][Full Text] [Related]
9. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction).
Thiele H; Eitel I; Meinberg C; Desch S; Leuschner A; Pfeiffer D; Hartmann A; Lotze U; Strauss W; Schuler G;
JACC Cardiovasc Interv; 2011 Jun; 4(6):605-14. PubMed ID: 21700245
[TBL] [Abstract][Full Text] [Related]
11. Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.
Farkouh ME; Reiffel J; Dressler O; Nikolsky E; Parise H; Cristea E; Baran DA; Dizon J; Merab JP; Lansky AJ; Mehran R; Stone GW
Circ Cardiovasc Interv; 2013 Jun; 6(3):216-23. PubMed ID: 23652600
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study.
Kosmidou I; Redfors B; Crowley A; Gersh B; Chen S; Dizon JM; Embacher M; Mehran R; Ben-Yehuda O; Mintz GS; Stone GW
Clin Cardiol; 2017 Nov; 40(11):982-987. PubMed ID: 28696573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction.
Bao MH; Zheng Y; Westerhout CM; Fu Y; Wagner GS; Chaitman B; Granger CB; Armstrong PW
J Electrocardiol; 2014; 47(4):465-71. PubMed ID: 24853083
[TBL] [Abstract][Full Text] [Related]
14. Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes.
Guptill JT; Mehta RH; Armstrong PW; Horton J; Laskowitz D; James S; Granger CB; Lopes RD
Circ Cardiovasc Interv; 2013 Apr; 6(2):176-83. PubMed ID: 23549644
[TBL] [Abstract][Full Text] [Related]
15. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
Hudson MP; Armstrong PW; O'Neil WW; Stebbins AL; Weaver WD; Widimsky P; Aylward PE; Ruzyllo W; Holmes D; Mahaffey KW; Granger CB
Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):183-92. PubMed ID: 21304097
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Tjandrawidjaja MC; Fu Y; Westerhout CM; Wagner GS; Granger CB; Armstrong PW;
Am J Cardiol; 2010 Sep; 106(5):630-4. PubMed ID: 20723636
[TBL] [Abstract][Full Text] [Related]
17. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Trendelenburg M; Theroux P; Stebbins A; Granger C; Armstrong P; Pfisterer M
Eur Heart J; 2010 May; 31(10):1181-7. PubMed ID: 20089518
[TBL] [Abstract][Full Text] [Related]
18. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial.
Toma M; Fu Y; Ezekowitz JA; McAlister FA; Westerhout CM; Granger CB; Armstrong PW
Am Heart J; 2010 Oct; 160(4):671-7. PubMed ID: 20934561
[TBL] [Abstract][Full Text] [Related]
19. Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segment-Elevation Myocardial Infarction Patients: Insights From the Vital Heart Response Registry.
Zheng Y; Bainey KR; Tyrrell BD; Brass N; Armstrong PW; Welsh RC
Circ Cardiovasc Interv; 2017 Nov; 10(11):. PubMed ID: 29146669
[TBL] [Abstract][Full Text] [Related]
20. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.
Herrmann HC; Lu J; Brodie BR; Armstrong PW; Montalescot G; Betriu A; Neuman FJ; Effron MB; Barnathan ES; Topol EJ; Ellis SG;
JACC Cardiovasc Interv; 2009 Oct; 2(10):917-24. PubMed ID: 19850249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
